Incretin

Quick definition. Incretins are hormones your gut releases when you eat. They tell the pancreas to release insulin before blood sugar climbs too high. The entire class of GLP-1 medications is built on copying this natural signal.

What an Incretin Is

An incretin is a metabolic hormone secreted by cells lining the intestine in response to food. Its defining job is to stimulate the pancreas to release insulin in a glucose-dependent way — that is, mainly when blood sugar is rising after a meal. The word combines "intestine," "secretion," and "insulin," capturing the idea of a gut signal that drives insulin output. The two principal incretins in humans are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).

The Incretin Effect

Researchers discovered incretins by noticing a striking phenomenon: glucose taken by mouth triggers a much larger insulin response than the same amount of glucose delivered intravenously. The difference — sometimes 50% or more of the total insulin response to a meal — is called the incretin effect, and it exists because oral glucose passes through the gut and releases incretin hormones that intravenous glucose bypasses. This effect is the body's way of anticipating an incoming sugar load and preparing for it.

Why Incretins Matter in Type 2 Diabetes

In people with type 2 diabetes, the incretin effect is substantially blunted. The pancreas responds less to GIP, and overall incretin signaling is weaker, contributing to the elevated post-meal blood sugar that characterizes the disease. Restoring or amplifying this signaling became one of the central strategies of modern diabetes treatment. Importantly, because incretin-based action is glucose-dependent, it carries a low risk of causing hypoglycemia compared with insulin or sulfonylureas.

How Medications Exploit the Incretin System

Natural incretins are broken down within minutes by an enzyme called DPP-4, which is why the body's own GLP-1 cannot be used as a drug directly. Pharmaceutical developers solved this in two ways. GLP-1 receptor agonists are engineered to resist DPP-4 degradation, so a single injection keeps stimulating the receptor for days. Separately, DPP-4 inhibitors (drugs ending in "-gliptin") block the enzyme to prolong the body's own incretins, though their effect is milder. The newest agents go further still: tirzepatide activates both the GIP and GLP-1 receptors at once, a dual-incretin approach.

The Incretin Era of Obesity Care

What began as diabetes research turned out to reshape obesity treatment. Because incretin receptors also sit in brain regions that govern appetite and satiety, amplifying incretin signaling reduces hunger and food intake. This is the mechanism behind the substantial weight loss seen with high-dose semaglutide and tirzepatide. The result is a class of medications that traces its entire lineage back to a simple observation about how the gut talks to the pancreas after a meal.